Durvalumab vs Lisinopril

Durvalumab vs Lisinopril: Overview

This comparison examines the pharmacological differences between Durvalumab and Lisinopril.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Lisinopril: ACE inhibitor preventing conversion of angiotensin I to angiotensin II.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Lisinopril — 12 hours.

Chemical Properties

Molecular Formula: Lisinopril — C21H31N3O5.

Molecular Weight: Lisinopril — 405.4900 g/mol.

Type: Durvalumab — Antibody; Lisinopril — Small molecule.